A Multicenter, Open-label, Sequential, Multiple-dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Efficacy or Eritoran in Descending Age Groups of Pediatric Subjects with Severe Sepsis
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Eritoran (Primary)
- Indications Sepsis
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Eisai Inc
- 05 Oct 2017 New trial record